Protein Kinase A in Prostate Cancer Tissue.

NCT05460312 | Unknown

• 1 other identifier: PKA-prostate
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Prostate cancer is the most common malignancy in men. documented risk factors of prostate cancer are age, ethnicity, various genomic mutations and family history of prostate cancer. The cellular mechanisms of malignant transformation are numerous and not completely understood. A possible mechanism is induction of an inflammation resulting in cellular atypia and pre-malignant changes in the affected tissue by inducing a pro-inflammatory response or changes in extra cellular matrix. Protein Kinase A (PKA) is a key stone enzyme in various intra-cellular processes. Various infections' inflammations and malignancies were proved to impact PKA activity. The research hypothesis is that prostate cancer tissue will show a unique profile of PKA activity, regulation and intracellular distribution.

Conditions

Prostate Neoplasm; Inflammation; Benign Hyperplasia of Prostate

Keywords

protein kinase A; immunohistochemistry; prostate cancer; prostate biopsy

Outcome Measures

Primary Outcomes (1)

• The distribution of PKA in prostate cancer versus benign tissue

  Immunohistochemical staining of paraffin sections of prostatebiopsies for PKA, western blot analysisi of tissue.

  1 year

Interventions

prostate biopsy DIAGNOSTIC_TEST

trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.

Eligibility Criteria

• Age: 50 Years+
• Gender Eligibility Details: Men referred to prostate biopsies.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A cohort of 100 consecutive men referred to prostate biopsy due to clinical suspicion of prosatet cancer.

You may qualify if:

• Men
• Clinical suspicion of prostate cancer
• Referred for biopsy
• Able to sign informed consent.

You may not qualify if:

• Previous prostate irradiation
• Chronic prostatitis
• Previous prostate surgery
• Recent urinary tract infection (3 months prior to biopsy).
• Indwelling urinary catheter

Sponsors & Collaborators

• Ziv Hospital: lead

MeSH Terms

Conditions

Prostatic Neoplasms; Inflammation; Prostatic Hyperplasia

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr. Ran Katz, Head, department of Urology, ziv medical center

Study Record Dates

• First Submitted: July 12, 2022
• First Posted: July 15, 2022
• Study Start: March 1, 2023
• Primary Completion: March 1, 2024
• Study Completion: May 1, 2024
• Last Updated: January 26, 2023

Record last verified: 2023-01